Clinical Evaluation of the Safety and Efficacy of the Phytomedicine APIVIRINE Based on Aqueous Extracts of Dichrostachys glomerata (Forssk.). Chiov. (D. cinerea) in COVID-19 Patients without Signs of Severity
Background: Since the appearance of the COVID-19 pandemic, several drugs have also been proposed for the treatment of the COVID-19, but the therapeutic effectiveness of those drugs is not satisfactory. This situation has led to the search for therapeutic solutions based on recipes from traditional medicine. Aims: This study aimed to evaluate the clinical safety, efficacy and tolerability of the phytomedicine APIVIRINE in patients with non-severe COVID-19. Methods: Patients were included following defined criteria and followed on an outpatient basis until recovery in accordance with national guidelines for the management of single cases of COVID-19 in Burkina Faso. Vital signs, anthropometric parameters as well as electrocardiographic, hematological and biochemical examinations were measured on D4, D7, D14 and D21. Adverse events were recorded during maintenance. Results: The present study included 45 patients. The clinical signs present at inclusion were mostly cough (44.44%), asthenia (42.22%), headache (40%), and anosmia (35.55%). Dyspnoea and chest pain were less represented in 05 (11.11%) and 06 (13.33%) patients. Cough, dyspnoea, chest pain, fever, sore throat, headache, and nasal obstruction present at inclusion disappeared before Day 4 of treatment. Anosmia and asthenia disappeared before Day 7. At the inclusion visit (Day 1), CRP, WBC, and blood glucose were abnormal in 15 (33.33%), 13 (28.89%), and 11 (24.44%) patients respectively. In addition, 3 (6.66%) patients had elevated creatinine levels. Transaminases Alanine aminotransferase (ALAT) were elevated in 05 (11.11%) patients while Aspartate aminotransferase (ASAT) was elevated in 04 (8.89%) patients. After 4 days of treatment, the cure rate was 33.33% of patients and 48.89% after 7 days. The cumulative cure rate was 86.67% after 14 days of treatment. Conclusion: No serious side effects or allergic reactions were observed during treatment. No clinical complications were observed and all symptoms present resolved on the 7th day of treatment.
References
[1]
Lone, S.A. and Ahmad, A. (2020) COVID-19 Pandemic—An African Perspective. Emerging Microbes & Infections, 9, 1300-1308. https://doi.org/10.1080/22221751.2020.1775132
Bonny, V., Maillard, A., Mousseaux, C., Plaçais, L. and Richier, Q. (2020) COVID-19: Physiopathologie d’une maladie à plusieurs visages. La Revue de Médecine Interne, 41, 375-389. https://doi.org/10.1016/j.revmed.2020.05.003
[4]
Rouamba, T., Barry, H., Ouédraogo, E., Tahita, M.C., Yaméogo, N.V., Poda, A., et al. (2021) Safety of Chloroquine or Hydroxychloroquine plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study. Therapeutics and Clinical Risk Management, 17, 1187-1198. https://doi.org/10.2147/TCRM.S330813
[5]
Zhang, X.-Y., Lv, L., Zhou, Y.-L., Xie, L.-D., Xu, Q., Zou, X.-F., et al. (2021) Efficacy and Safety of Xiyanping Injection in the Treatment of COVID-19: A Multicenter, Prospective, Open-Label and Randomized Controlled Trial. Phytotherapy Research, 35, 4401-4410. https://doi.org/10.1002/ptr.7141
[6]
Organisation Mondiale de la Santé. (2014) Médecine traditionnelle. Rapport du Secrétariat, Report No. A67/26. OMS, 6.
[7]
Organisation Mondiale de la Santé (2021) Médecine traditionnelle et complémentaire. Report No. WPR/RC72/6. OMS, Geneva, 6.
[8]
WHO (2020) WHO, Africa CDC Push for COVID-19 Traditional Medicine Research in Africa. https://www.who.int/news-room/feature-stories/detail/who-africa-cdc-push-for-covid-19-traditional-medicine-research-in-africa
[9]
Alam, S., Sarker, M.M.R., Afrin, S., Richi, F.T., Zhao, C., Zhou, J.-R., et al. (2021). Traditional Herbal Medicines, Bioactive Metabolites, and Plant Products against COVID-19: Update on Clinical Trials and Mechanism of Actions. Frontiers in Pharmacology, 12, Article 671498. https://doi.org/10.3389/fphar.2021.671498
[10]
Ren, W., Ma, Y., Wang, R., Liang, P., Sun, Q., Pu, Q., et al. (2021) Research Advance on Qingfei Paidu Decoction in Prescription Principle, Mechanism Analysis and Clinical Application. Frontiers in Pharmacology, 11, Article 589714. https://doi.org/10.3389/fphar.2020.589714
[11]
Shah, T., Shah, Z., Xia, K.-Y. and Baloch, Z. (2022) Therapeutic Mechanisms and Impact of Traditional Chinese Medicine on COVID-19 and Other Influenza Diseases. Pharmacological Research—Modern Chinese Medicine, 2, Article ID: 100029. https://doi.org/10.1016/j.prmcm.2021.100029
[12]
Wen, J., Wang, R., Liu, H., Tong, Y., Wei, S., Zhou, X., et al. (2020) Potential Therapeutic Effect of Qingwen Baidu Decoction against Corona Virus Disease 2019: A Mini Review. Chinese Medicine, 15, Article No. 48. https://doi.org/10.1186/s13020-020-00332-y
[13]
Abou Zeid, A.H., Hifnawy, M.S. and Mohammed, R.S. (2009) Phenolic Compounds and Biological Activities of Dichrostachys cinerea L. Medicinal and Aromatic Plant Science and Biotechnology, 3, 42-49.
[14]
Vijayalakshmi, M., Periyanayagam, K. and Lakshmana, P.S. (2010) Invitro Antilice Activity of Dichrostachys cinerea (L.) Wight & Arn. International Journal of PharmTech Research, 2, 2210-2213.
[15]
Neondo, J.O., Mbithe, C.M., Njenga, P.K. and Muthuri, C.W. (2012) Phytochemical Characterization, Antibacterial Screening and Toxicity Evaluation of Dichrostachys Cinerea. International Journal of Medicinal Plants Research, 1, 32-37.
[16]
El-Sharawy, R.T., Elkhateeb, A., Marzouk, M.M., Abd El-Latif, R.R., Abdelrazig, S.E. and El-Ansari, M.A. (2017) Antiviral and Antiparasitic Activities of Clovamide: The Major Constituent of Dichrostachys cinerea (L.) Wight et Arn. Journal of Applied Pharmaceutical Science, 7, 219-223.
[17]
Agrawal, P.K., Agrawal, C. and Blunden, G. (2020) Quercetin: Antiviral Significance and Possible COVID-19 Integrative Considerations. Natural Product Communications, 15, Article ID: 1934578X2097629. https://doi.org/10.1177/1934578X20976293
[18]
Al-Shuhaib, M.B.S., Hashim, H.O. and Al-Shuhaib, J.M.B.(2022) Epicatechin Is a Promising Novel Inhibitor of SARS-CoV-2 Entry by Disrupting Interactions Between Angiotensin-Converting Enzyme Type 2 and the Viral Receptor Binding Domain: A Computational/Simulation Study. Computers in Biology and Medicine, 141, Article ID: 105155. https://doi.org/10.1016/j.compbiomed.2021.105155
[19]
Diniz, L.R.L., Elshabrawy, H.A., de Santana Souza, M.T., Duarte, A.B.S., Datta, S. and de Sousa, D.P. (2021) Catechins: Therapeutic Perspectives in COVID-19-Associated Acute Kidney Injury. Molecules, 26, Article No. 5951. https://doi.org/10.3390/molecules26195951
[20]
Liskova, A., Samec, M., Koklesova, L., Samuel, S.M., Zhai, K., Al-Ishaq, R.K., et al. (2021) Flavonoids against the SARS-CoV-2 Induced Inflammatory Storm. Biomedicine & Pharmacotherapy, 138, Article ID: 111430. https://doi.org/10.1016/j.biopha.2021.111430
[21]
Cohen, J. (1988) Statistical Power Analysis for the Behavioral Sciences. 2nd Edition, Erlbaum Associates, Hillsdale.
[22]
Meo, S.A., Klonoff, D.C. and Akram, J. (2020) Efficacy of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19. European Review for Medical and Pharmacological Sciences, 24, 4539-4547.
[23]
Deeks, J.J., Dinnes, J., Takwoingi, Y., Davenport, C., Spijker, R., Taylor-Phillips, S., et al. (2020) Antibody Tests for Identification of Current and Past Infection with SARS-CoV-2. Cochrane Database of Systematic Reviews, No. 6, Article No. CD013652. https://doi.org/10.1002/14651858.CD013652
[24]
Liang, S.-B., Zhang, Y.-Y., Shen, C., Liang, C.-H., Lai, B.-Y., Dai, N., et al. (2021) Chinese Herbal Medicine Used with or without Conventional Western Therapy for COVID-19: An Evidence Review of Clinical Studies. Frontiers in Pharmacology, 11, Article 583450. https://doi.org/10.3389/fphar.2020.583450
[25]
Rabier, V., Dubée, V., Abgueguen, P., Mahieux, R., Delbos, V., Fialaire, P., et al. (2020) Réévaluation à distance de la symptomatologie des patients atteints de forme légère à modérée de COVID-19. Médecine et Maladies Infectieuses, 50, S79. https://doi.org/10.1016/j.medmal.2020.06.156
[26]
Babu, P.S., Krishna, V., Maruthi, K., Shankarmurthy, K. and Babu, R. (2011) E Evaluation of Acute Toxicity and Hepatoprotective Activity of the Methanolic Extract of Dichrostachys Cinerea (Wight and Arn.) Leaves. Pharmacognosy Research, 3, 40-43. https://doi.org/10.4103/0974-8490.79114
[27]
Kothari, S.C., Shivarudraiah, P., Venkataramaiah, S.B., Gavara, S., Arumugam, S.N. and Soni, M.G. (2014) Toxicologic Evaluation of Dichrostachys glomerata Extract: Subchronic Study in Rats and Genotoxicity Tests. Food and Chemical Toxicology, 69, 120-131. https://doi.org/10.1016/j.fct.2014.03.045
[28]
Kullar, R., Patel, A.P. and Saab, S. (2020) Hepatic Injury in Patients with COVID-19. Journal of Clinical Gastroenterology, 54, 841-849. https://doi.org/10.1097/MCG.0000000000001432
[29]
Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 382, 1708-1720. https://doi.org/10.1056/NEJMoa2002032
[30]
Wang, Y., Liu, Y., Liu, L., Wang, X., Luo, N. and Li, L. (2020) Clinical Outcomes in 55 Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China. The Journal of Infectious Diseases, 221, 1770-1774. https://doi.org/10.1093/infdis/jiaa119
[31]
Bénézit, F., Armange, L., Picard, L., Paz, D.L., Pronier, C., Patrat-Delon, S., et al. (2020) Histoire naturelle de la COVID-19 avec suivi prospectif systématique standardisé: Combien de temps durent les symptômes? Médecine et Maladies Infectieuses, 50, S79. https://doi.org/10.1016/j.medmal.2020.06.157
[32]
Liu, B., Jayasundara, D., Pye, V., Dobbins, T., Dore, G.J., Matthews, G., et al. (2021) Whole of Population-Based Cohort Study of Recovery Time from COVID-19 in New South Wales Australia. The Lancet Regional Health—Western Pacific, 12, Article ID: 100193. https://doi.org/10.1016/j.lanwpc.2021.100193
[33]
Abou Zeid, A.H., Hifnawy, M.S., Mohammed, R.S. and Sleem, A.A. (2015) Lipoidal Contents, Analgesic and Antipyretic Activities of the Aerial Parts of Dichrostachys cinerea L. Journal of Herbs, Spices & Medicinal Plants, 21, 118-128. https://doi.org/10.1080/10496475.2014.920459
[34]
Irié-N’guessan, G., et al. (2011) Tracheal Relaxation of Five Ivorian Anti-Asthmatic Plants: Role of Epithelium and K+ Channels in the Effect of the Aqueous-Alcoholic Extract of Dichrostachys cinerea Root Bark. Journal of Ethnopharmacology, 138, 432-438. https://doi.org/10.1016/j.jep.2011.09.016
[35]
Kuate, D., Etoundi, B.C., Ngondi, J.L., Muda, W. and Oben, J.E. (2013) Anti-Inflammatory, Anthropometric and Lipomodulatory Effects Dyglomera® (Aqueous Extract of Dichrostachys glomerata) in Obese Patients with Metabolic Syndrome. Functional Foods in Health and Disease, 3, 416-427. https://doi.org/10.31989/ffhd.v3i11.35
[36]
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., et al. (2020) A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine, 382, 1787-99. https://doi.org/10.1056/NEJMoa2001282
[37]
Wang, Y., Lu, C., Li, H., Qi, W., Ruan, L., Bian, Y., et al. (2021) Efficacy and Safety Assessment of Severe COVID-19 Patients with Chinese Medicine: A Retrospective Case Series Study at Early Stage of the COVID-19 Epidemic in Wuhan, China. Journal of Ethnopharmacology, 277, Article ID: 113888. https://doi.org/10.1016/j.jep.2021.113888
[38]
Kudi, A.C. and Myint, S.H. (1999) Antiviral Activity of Some Nigerian Medicinal Plant Extracts. Journal of Ethnopharmacology, 68, 289-294. https://doi.org/10.1016/S0378-8741(99)00049-5
[39]
Khazdair, M.R., Anaeigoudari, A. and Agbor, G.A. (2021) Anti-Viral and Anti-Inflammatory Effects of Kaempferol and Quercetin and COVID-2019: A Scoping Review. Asian Pacific Journal of Tropical Biomedicine, 11, 327-334. https://doi.org/10.4103/2221-1691.319567
[40]
Farhat, A., Ben Hlima, H., Khemakhem, B., Ben Halima, Y., Michaud, P., Abdelkafi, S., et al. (2022) Apigenin Analogues as SARS-CoV-2 Main Protease Inhibitors: In-Silico Screening Approach. Bioengineered, 13, 3350-3361. https://doi.org/10.1080/21655979.2022.2027181
